• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Advantages and Disadvantages of Mammography Screening.乳腺钼靶筛查的优缺点
Breast Care (Basel). 2011;6(3):199-207. doi: 10.1159/000329005. Epub 2011 May 27.
2
3
Responding to the challenges of breast cancer in egypt and other arab countries.应对埃及及其他阿拉伯国家乳腺癌带来的挑战。
J Egypt Natl Canc Inst. 2008 Dec;20(4):309-12.
4
Mammography screening: A major issue in medicine.乳腺 X 光筛查:医学中的一个重大问题。
Eur J Cancer. 2018 Feb;90:34-62. doi: 10.1016/j.ejca.2017.11.002. Epub 2017 Dec 20.
5
Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.针对40至49岁患乳腺癌平均风险女性的乳腺钼靶筛查:一项基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.
6
7
8
Benefits and Harms of Breast Cancer Screening: A Systematic Review.乳腺癌筛查的获益与危害:系统评价。
JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183.
9
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.流行病学方法与应用概述:观察性研究设计的优势与局限性。
Crit Rev Food Sci Nutr. 2010;50 Suppl 1(s1):10-2. doi: 10.1080/10408398.2010.526838.
10
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation.乳腺癌筛查的危害:系统评价更新 2009 年美国预防服务工作组建议。
Ann Intern Med. 2016 Feb 16;164(4):256-67. doi: 10.7326/M15-0970. Epub 2016 Jan 12.

引用本文的文献

1
End-to-end CNN-based deep learning enhances breast lesion characterization using quantitative ultrasound (QUS) spectral parametric images.基于端到端卷积神经网络的深度学习利用定量超声(QUS)频谱参数图像增强了乳腺病变特征描述。
Sci Rep. 2025 Sep 25;15(1):32805. doi: 10.1038/s41598-025-15772-5.
2
Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence.用于检测和监测乳腺癌复发的非侵入性生物标志物的进展。
Sci Prog. 2025 Jul-Sep;108(3):368504251362350. doi: 10.1177/00368504251362350. Epub 2025 Aug 19.
3
Breast Cancer Detection Using Infrared Thermography: A Survey of Texture Analysis and Machine Learning Approaches.使用红外热成像技术检测乳腺癌:纹理分析和机器学习方法综述
Bioengineering (Basel). 2025 Jun 11;12(6):639. doi: 10.3390/bioengineering12060639.
4
Efficacy of Modified Triple Assessment in Diagnosing Breast Lesions: A Prospective Observational Study.改良三联评估法在诊断乳腺病变中的效能:一项前瞻性观察性研究
Cureus. 2025 Mar 31;17(3):e81538. doi: 10.7759/cureus.81538. eCollection 2025 Mar.
5
Development of Iron Oxide Nanochains as a Sensitive Magnetic Particle Imaging Tracer for Cancer Detection.氧化铁纳米链作为用于癌症检测的灵敏磁性粒子成像示踪剂的研发。
ACS Appl Mater Interfaces. 2025 Apr 9;17(14):20859-20871. doi: 10.1021/acsami.5c00332. Epub 2025 Mar 26.
6
[Personalized profiling in the field of senology].[乳腺病学领域的个性化分析]
Radiologie (Heidelb). 2025 Mar;65(3):194-200. doi: 10.1007/s00117-024-01410-0. Epub 2025 Jan 22.
7
The Screening Tomosynthesis Trial with Advanced Reader Methods (STREAM): design and rationale of a population-based breast cancer screening trial.采用先进阅片方法的乳腺断层合成筛查试验(STREAM):一项基于人群的乳腺癌筛查试验的设计与原理
Eur Radiol. 2025 Jan 9. doi: 10.1007/s00330-024-11324-z.
8
A Case-control Study on the Association of Fruit and Vegetable Consumption with Risk of Breast Cancer.一项关于水果和蔬菜摄入量与乳腺癌风险关联的病例对照研究。
Int J Prev Med. 2024 Oct 18;15:56. doi: 10.4103/ijpvm.ijpvm_129_23. eCollection 2024.
9
Evaluating qualitative data analysis workshops from the perspective of public contributors.从公众参与者的角度评估定性数据分析研讨会。
Res Involv Engagem. 2024 Sep 27;10(1):99. doi: 10.1186/s40900-024-00628-5.
10
Assessing Breast Cancer through Tumor Microenvironment Mapping of Collagen and Other Biomolecule Spectral Fingerprints─A Review.通过肿瘤微环境中胶原和其他生物分子光谱指纹图谱评估乳腺癌——综述。
ACS Sens. 2024 Sep 27;9(9):4364-4379. doi: 10.1021/acssensors.4c00585. Epub 2024 Aug 22.

本文引用的文献

1
Increasingly strong reduction in breast cancer mortality due to screening.由于筛查,乳腺癌死亡率呈大幅下降趋势。
Br J Cancer. 2011 Mar 15;104(6):910-4. doi: 10.1038/bjc.2011.44. Epub 2011 Feb 22.
2
Risk of radiation-induced breast cancer from mammographic screening.乳腺 X 线筛查所致辐射诱导乳腺癌的风险。
Radiology. 2011 Jan;258(1):98-105. doi: 10.1148/radiol.10100655. Epub 2010 Nov 16.
3
Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes.假阳性乳腺 X 光片对一般和特定心理社会结果影响的荟萃分析。
Psychooncology. 2010 Oct;19(10):1026-34. doi: 10.1002/pon.1676.
4
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England.从一项随机试验和英国乳腺癌筛查计划中得出的乳腺癌筛查中挽救的生命绝对数量和过度诊断。
J Med Screen. 2010;17(1):25-30. doi: 10.1258/jms.2009.009094.
5
Screening for breast cancer: an update for the U.S. Preventive Services Task Force.乳腺癌筛查:美国预防服务工作组的更新。
Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42. doi: 10.7326/0003-4819-151-10-200911170-00009.
6
An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence.佛罗伦萨启动乳腺 X 光筛查 15 年后的过度诊断估计。
Eur J Cancer. 2009 Dec;45(18):3166-71. doi: 10.1016/j.ejca.2009.06.014. Epub 2009 Oct 29.
7
Screening for breast cancer with mammography.通过乳房X线摄影术筛查乳腺癌。
Cochrane Database Syst Rev. 2009 Oct 7(4):CD001877. doi: 10.1002/14651858.CD001877.pub3.
8
Imaging studies for the early detection of breast cancer.用于乳腺癌早期检测的影像学研究。
Dtsch Arztebl Int. 2008 Aug;105(31-32):541-7. doi: 10.3238/arztebl.2008.0541. Epub 2008 Aug 4.
9
Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends.公共组织的乳腺钼靶筛查项目中的过度诊断:发病率趋势的系统评价
BMJ. 2009 Jul 9;339:b2587. doi: 10.1136/bmj.b2587.
10
How effective are breast cancer screening programmes by mammography? Review of the current evidence.乳房X光检查的乳腺癌筛查项目效果如何?当前证据综述。
Eur J Cancer. 2009 Jul;45(11):1916-23. doi: 10.1016/j.ejca.2009.03.022. Epub 2009 Apr 22.

乳腺钼靶筛查的优缺点

Advantages and Disadvantages of Mammography Screening.

作者信息

Heywang-Köbrunner Sylvia H, Hacker Astrid, Sedlacek Stefan

机构信息

Referenzzentrum Mammographie München, Germany.

出版信息

Breast Care (Basel). 2011;6(3):199-207. doi: 10.1159/000329005. Epub 2011 May 27.

DOI:10.1159/000329005
PMID:21779225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3132967/
Abstract

Mammography screening is the only method presently considered appropriate for mass screening of asymptomatic women. Its frequent use, however, warrants diligent analysis of potential side effects. Radiation risk is far below the natural yearly risk of breast cancer and should not be used as an argument against screening. False-positive calls lead to additional imaging or histopathological assessment, mainly percutaneous breast biopsy. These measures are tolerated and accepted fairly well. Their number is limited by strict quality assurance and constant training. Interval cancers represent a limitation of breast screening that should prompt further research for optimization. Evaluation of overdiagnosis is a highly debated topic in the literature. According to the probably most realistic available calculations, overdiagnosis is acceptable as it is compensated by the potential mortality reduction. Nonetheless, this potential side effect warrants optimal adjustment of therapy to the patient's individual risk. The mortality reduction seen in randomized studies was confirmed by results from national screening programs. A recent case referent study indicated that improvements in mortality reduction run parallel to improved mammographic techniques. Use of less aggressive therapies is another valuable effect of screening. Awareness of potential problems, strict quality assurance, and further research should help to further develop screening programs.

摘要

乳腺钼靶筛查是目前唯一被认为适用于无症状女性群体筛查的方法。然而,其频繁使用需要对潜在副作用进行认真分析。辐射风险远低于乳腺癌的自然年度风险,不应被用作反对筛查的理由。假阳性结果会导致进一步的影像学检查或组织病理学评估,主要是经皮乳房活检。这些措施的耐受性和接受度相当不错。其数量受到严格质量保证和持续培训的限制。间期癌是乳腺筛查的一个局限性,应促使进一步研究以进行优化。过度诊断的评估是文献中一个备受争议的话题。根据可能最现实的现有计算,过度诊断是可以接受的,因为它被潜在的死亡率降低所抵消。尽管如此,这种潜在的副作用仍需要根据患者的个体风险对治疗进行优化调整。随机研究中观察到的死亡率降低得到了国家筛查项目结果的证实。最近一项病例对照研究表明,死亡率降低的改善与乳腺钼靶技术的改进同步。采用侵入性较小的治疗方法是筛查的另一个有益效果。认识到潜在问题、严格的质量保证以及进一步的研究应有助于进一步完善筛查项目。